Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 159

Sort by

Sort Order Select

Journal Articles

Prognostic significance of IKZF1 deletion subtypes in ph-negative BCP-ALL: Biallelic-null deletion predicts the worst survival in TP53-wild type patients

Seung-Hwan Lee, Daehun Kwag, Gi June Min, Sung-Soo Park, Silvia Park, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Heeje Kim, Chang-Ki Min, Seok-Goo Cho, Jae-Ho Yoon

Blood (2025) 146 (Supplement 1): 5149.

https://doi.org/10.1182/blood-2025-5149

Published: 2025

Journal Articles

A phase 1/2a trial of amsulostat, a novel pan-lysyl oxidase inhibitor, in patients with advanced myelofibrosis as an add-on to ruxolitinib treatment for up to 52 weeks

Ross Baker, Chih-Cheng Chen, Tsai-Yun Chen, Stanley Cheung, Hui-Hua Hsiao, Jae Hoon Lee, Ji Yun Lee, Sung-Eun Lee, Won Sik Lee, Lucia Masarova, Peter Tan, Shuhying Tan, Pankit Vachhani, Anne Marie Watson, Shang-Ju Wu, Jana Baskar, Joanna Leadbetter, Wolfgang Jarolimek

Blood (2025) 146 (Supplement 1): 2027.

https://doi.org/10.1182/blood-2025-2027

Published: 2025

Journal Articles

Transcriptomic signatures associated with deep molecular response to ropeginterferon alfa-2b in polycythemia vera

Seug Yun Yoon, Sung-Soo Yoon, Deok-Hwan Yang, Gyeong-Won Lee, Sang Kyun Sohn, Ho-Jin Shin, Sung Hwa Bae, Chul Won Choi, Eun-Ji Choi, June-Won June-Won, Soo-Mee Bang, Joon Seong Park, Yong Park, Young Hoon Park, Sung-Eun Lee

Blood (2025) 146 (Supplement 1): 2040.

https://doi.org/10.1182/blood-2025-2040

Published: 2025

Journal Articles

Clinical significance of earlier CHR achievement and long-term CHR maintenance in polycythemia vera patients treated with ropeginterferon alfa-2b

Sung-Eun Lee, Sung-Soo Yoon, Deok-Hwan Yang, Gyeong-Won Lee, Seug Yun Yoon, Sang Kyun Sohn, Ho-Jin Shin, Sung Hwa Bae, Chul Won Choi, Yunsuk Choi, June-won Cheong, Soo-Mee Bang, Joon Seong Park, Jong Wook Lee, Yong Park, Young Hoon Park

Blood (2025) 146 (Supplement 1): 5598.

https://doi.org/10.1182/blood-2025-5598

Published: 2025

Journal Articles

Phase 3 randomized double-blind study evaluating selinexor, an XPO1 inhibitor, plus ruxolitinib in jaki-naïve myelofibrosis: Study rationale and preliminary patient characteristics

Blood (2025) 146 (Supplement 1): 7353.

https://doi.org/10.1182/blood-2025-7353

Published: 2025

Journal Articles

Comparative efficacy of TBI-based vs. non-TBI reduced toxicity conditioning regimens in adult ALL undergoing allogeneic HCT in CR1: Improved outcomes with TBI-based RTC and ATG/ptcy combination

Kyung won Park, Jaehyun Ahn, Daehun Kwag, Sung-Soo Park, Silvia Park, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Heeje Kim, Chang-Ki Min, Seok-Goo Cho, Jae-Ho Yoon

Blood (2025) 146 (Supplement 1): 4213.

https://doi.org/10.1182/blood-2025-4213

Published: 2025

Journal Articles

Revisiting the role of second allogeneic HCT for post-transplant relapse in acute lymphoblastic leukemia: Comparative outcomes in the era of targeted therapies

Jaehyun Ahn, Daehun Kwag, Gi June Min, Sung-Soo Park, Silvia Park, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Heeje Kim, Chang-Ki Min, Seok-Goo Cho, Jae-Ho Yoon

Blood (2025) 146 (Supplement 1): 1548.

https://doi.org/10.1182/blood-2025-1548

Published: 2025

Journal Articles

Durable efficacy and long-term safety with pelabresib plus ruxolitinib in JAK Inhibitor–Naive myelofibrosis: 96-week Results from the Phase III MANIFEST-2 study

Blood (2025) 146 (Supplement 1): 910.

https://doi.org/10.1182/blood-2025-910

Published: 2025

Journal Articles

Rapid JAK2 V617F decline predicts response durability: Kinetics of JAK2 V617F in ropeginterferon alfa-2b treated polycythemia vera

Blood (2025) 146 (Supplement 1): 3819.

https://doi.org/10.1182/blood-2025-3819

Published: 2025

Journal Articles

Clinical outcomes and prognostic factors in AML patients undergoing second allogeneic hematopoietic stem cell transplantation

Hohyung Nam, Byung-Sik Cho, Hyunyee Rosa Cho, Ka Young Kim, Kyoung Il Min, So Yeon Park, Daehun Kwag, Seonggyu Byeon, Gi-June Min, Jung Yeon Lee, Sung-Soo Park, Silvia Park, Jae-Ho Yoon, Sung-Eun Lee, Ki-Seong Eom, Yoo-Jin Kim, Chang-Ki Min, Seok-Goo Cho, Heeje Kim

Blood (2025) 146 (Supplement 1): 7707.

https://doi.org/10.1182/blood-2025-7707

Published: 2025

Journal Articles

MRD-guided outcome analysis of ponatinib plus hyper-CVAD versus historical imatinib in ph-positive ALL: Impact of early response and dose-adjusted ponatinib

Kyoung Il Min, Daehun Kwag, Gi June Min, Sung-Soo Park, Silvia Park, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Heeje Kim, Chang-Ki Min, Seok-Goo Cho, Jae-Ho Yoon

Blood (2025) 146 (Supplement 1): 3327.

https://doi.org/10.1182/blood-2025-3327

Published: 2025

Journal Articles

Impact of initial FLT3-ITD mutated clone numbers on clinical outcomes in Acute Myeloid Leukemia

Daehun Kwag, Gi June Min, Sung-Soo Park, Silvia Park, Jae-Ho Yoon, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Chang-Ki Min, Seok-Goo Cho, Heeje Kim

Blood (2025) 146 (Supplement 1): 1638.

https://doi.org/10.1182/blood-2025-1638

Published: 2025

Journal Articles

Clinical significance of apoe genotypes in older adults with Acute Myeloid Leukemia: Insights from a consecutively treated cohort

Daehun Kwag, Byung-Sik Cho, Gi June Min, Sung-Soo Park, Silvia Park, Jae-Ho Yoon, Sung-Eun Lee, Ki-Seong Eom, Yoo-Jin Kim, Chang-Ki Min, Seok-Goo Cho, Heeje Kim

Blood (2025) 146 (Supplement 1): 1636.

https://doi.org/10.1182/blood-2025-1636

Published: 2025

Journal Articles

Evaluating the Impact of Absolute Lymphocyte Count on Outcomes in ATG Containing Haploidentical HSCT for Acute Myeloid Leukemia

Daehun Kwag, Jung Yeon Lee, Gi June Min, Sung-Soo Park, Silvia Park, Jae-Ho Yoon, Sung-Eun Lee, Ki-Seong Eom, Yoo-Jin Kim, Seok Lee, Hee-Je Kim, Chang-Ki Min, Seok-Goo Cho, Byoung-Sik Cho

Blood (2024) 144 (Supplement 1): 7327.

https://doi.org/10.1182/blood-2024-212406

Published: 2024

Journal Articles

Real-World Wutcome of Defibrotide for Treatment of Adult Patients Who Developed Severe Hepatic VOD/SOS after Allogeneic Hematopoietic Cell Transplantation

Jae-Ho Yoon, Daehun Kwag, Gi June Min, Sung-Soo Park, Silvia Park, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Hee-Je Kim, Chang-Ki Min, Seok-Goo Cho, Seok Lee

Blood (2024) 144 (Supplement 1): 7326.

https://doi.org/10.1182/blood-2024-212062

Published: 2024

Journal Articles

Ropeginterferon in Low-Risk Patients with Polycythemia Vera

Ji Yun Lee, Sung-Eun Lee, Sung-Soo Yoon, Deok-Hwan Yang, Sang Kyun Sohn, Seug Yun Yoon, Soo-Mee Bang, Gyeong Won Lee, Chul Won Choi, Yunsuk Choi, June-Won Cheong, Young Hoon Park

Blood (2024) 144 (Supplement 1): 1799.

https://doi.org/10.1182/blood-2024-202345

Published: 2024

Journal Articles

Impact of Concurrent IKZF1 and CDKN2 Deletions on Prognostic Outcomes in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation

So Yeon Park, Jae-Ho Yoon, Daehun Kwag, Jung Yeon Lee, Gi June Min, Sung-Soo Park, Silvia Park, Sung-Eun Lee, Byoung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Hee-Je Kim, Chang-Ki Min, Seok-Goo Cho, Seok Lee

Blood (2024) 144 (Supplement 1): 4220.

https://doi.org/10.1182/blood-2024-212342

Published: 2024

Journal Articles

Multicenter, Open-Label Phase 1/2a Study of Pxs-5505 and Ruxolitinib in Patients with Primary, Post-Polycythemia Vera (PV) or Post-Essential Thrombocythemia (ET) Myelofibrosis

Peter Tan, Ross Baker, Sung-Eun Lee, Anne Marie Watson, Stanley Cheung, Shang-Ju Wu, Chih-Cheng Chen, Shuhying Tan, Pankit Vachhani, Tsai-Yun Chen, Jae Hoon Lee, Hui-Hua Hsiao, Ji Yun Lee, Won Sik Lee, Lucia Masarova, Jana Baskar, Wolfgang Jarolimek, Joanna Leadbetter

Blood (2024) 144 (Supplement 1): 1001.

https://doi.org/10.1182/blood-2024-204290

Published: 2024

Journal Articles

Real-World Experience of Blinatumomab for 8 Years Regarding Predictive Factors Including Lymphocyte Kinetics for Response and Survival Outcome in Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia

Seonghan Lee, Jae-Ho Yoon, Daehun Kwag, Gi-June Min, Sung-Soo Park, Silvia Park, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Hee-Je Kim, Chang-Ki Min, Seok-Goo Cho, Seok Lee

Blood (2024) 144 (Supplement 1): 5903.

https://doi.org/10.1182/blood-2024-205680

Published: 2024

Journal Articles

Feasibility of TBI-Augmented Reduced Toxicity Conditioning Regimen with ATG/Ptcy Combination for Haploidentical Donor Transplantation in Adult Acute Lymphoblastic Leukemia

Jaehyun Ahn, Jae-Ho Yoon, Daehun Kwag, Gi June Min, Sung-Soo Park, Silvia Park, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Hee-Je Kim, Chang-Ki Min, Seok-Goo Cho, Seok Lee

Blood (2024) 144 (Supplement 1): 4892.

https://doi.org/10.1182/blood-2024-207284

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Prognostic significance of IKZF1 deletion subtypes in ph-negative BCP-ALL: Biallelic-null deletion predicts the worst survival in TP53-wild type patients

A phase 1/2a trial of amsulostat, a novel pan-lysyl oxidase inhibitor, in patients with advanced myelofibrosis as an add-on to ruxolitinib treatment for up to 52 weeks

Transcriptomic signatures associated with deep molecular response to ropeginterferon alfa-2b in polycythemia vera

Clinical significance of earlier CHR achievement and long-term CHR maintenance in polycythemia vera patients treated with ropeginterferon alfa-2b

Phase 3 randomized double-blind study evaluating selinexor, an XPO1 inhibitor, plus ruxolitinib in jaki-naïve myelofibrosis: Study rationale and preliminary patient characteristics

Comparative efficacy of TBI-based vs. non-TBI reduced toxicity conditioning regimens in adult ALL undergoing allogeneic HCT in CR1: Improved outcomes with TBI-based RTC and ATG/ptcy combination

Revisiting the role of second allogeneic HCT for post-transplant relapse in acute lymphoblastic leukemia: Comparative outcomes in the era of targeted therapies

Durable efficacy and long-term safety with pelabresib plus ruxolitinib in JAK Inhibitor–Naive myelofibrosis: 96-week Results from the Phase III MANIFEST-2 study

Rapid JAK2 V617F decline predicts response durability: Kinetics of JAK2 V617F in ropeginterferon alfa-2b treated polycythemia vera

Clinical outcomes and prognostic factors in AML patients undergoing second allogeneic hematopoietic stem cell transplantation

MRD-guided outcome analysis of ponatinib plus hyper-CVAD versus historical imatinib in ph-positive ALL: Impact of early response and dose-adjusted ponatinib

Impact of initial FLT3-ITD mutated clone numbers on clinical outcomes in Acute Myeloid Leukemia

Clinical significance of apoe genotypes in older adults with Acute Myeloid Leukemia: Insights from a consecutively treated cohort

Evaluating the Impact of Absolute Lymphocyte Count on Outcomes in ATG Containing Haploidentical HSCT for Acute Myeloid Leukemia

Real-World Wutcome of Defibrotide for Treatment of Adult Patients Who Developed Severe Hepatic VOD/SOS after Allogeneic Hematopoietic Cell Transplantation

Ropeginterferon in Low-Risk Patients with Polycythemia Vera

Impact of Concurrent IKZF1 and CDKN2 Deletions on Prognostic Outcomes in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation

Multicenter, Open-Label Phase 1/2a Study of Pxs-5505 and Ruxolitinib in Patients with Primary, Post-Polycythemia Vera (PV) or Post-Essential Thrombocythemia (ET) Myelofibrosis

Real-World Experience of Blinatumomab for 8 Years Regarding Predictive Factors Including Lymphocyte Kinetics for Response and Survival Outcome in Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia

Feasibility of TBI-Augmented Reduced Toxicity Conditioning Regimen with ATG/Ptcy Combination for Haploidentical Donor Transplantation in Adult Acute Lymphoblastic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only